<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE1D1D4E-03D6-4D45-9048-74BFF08DA68A"><gtr:id>EE1D1D4E-03D6-4D45-9048-74BFF08DA68A</gtr:id><gtr:name>Peptinnovate Limited</gtr:name><gtr:address><gtr:line1>90 HIGH HOLBORN</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>WC1V 6XX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE1D1D4E-03D6-4D45-9048-74BFF08DA68A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>EE1D1D4E-03D6-4D45-9048-74BFF08DA68A</gtr:id><gtr:name>Peptinnovate Limited</gtr:name><gtr:address><gtr:line1>90 HIGH HOLBORN</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>WC1V 6XX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>100000.0</gtr:offerGrant><gtr:projectCost>177711.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/191FE3DD-C0AB-4B41-891B-AD205756E805"><gtr:id>191FE3DD-C0AB-4B41-891B-AD205756E805</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Lightfoot</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710703"><gtr:id>46C45A98-52D9-4006-B44C-2A372E47616F</gtr:id><gtr:title>Disease Modification of Asthma by molecules derived from TB bacteria</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710703</gtr:grantReference><gtr:abstractText>Tuberculosis bacteria (mTB) are present in about 2 billion people worldwide; they have
evolved over millennia to remain hidden in the body by producing proteins that modulate the
host's immune system. These proteins have been shown to interact with and reduce the body's
natural inflammatory processes.
Peptinnovate?s innovation
Peptinnovate?s approach is to unlock the anti-inflammatory activity of these proteins and to
develop new medicines for debilitating diseases such as asthma and COPD. Building on
evolution, nature's ingenuity and employing Peptinnovate?s drug discovery and development
skills we have modified these proteins to more drug-like molecules and are progressing the
candidate molecule, PIN201104, to the clinic.
Aims
Following exciting preclinical data in the murine house dust mite (HDM) asthma model for
the lead candidate PIN201104 Peptinnovate will progress the molecule into in vivo and in
vitro mechanism of action studies to; unravel the mechanism of action of the peptide in
asthma animal models and translate this mechanism into an in vitro setting in human cells.
These studies will then lead to an in vitro biomarker assay for use in clinical studies in healthy
volunteers and guide phenotypic positioning of PIN201104 in severe, steroid refractive
asthma.
Objectives
? To perform in vivo studies in murine asthma models to determine if PIN201104
effects airway hyperreactivity (asthma)
? To perform in vivo studies to ascertain the appropriate dosing regimen and route of
delivery for PIN201104 for the treatment of asthma
Benefits, outcomes and impacts
The worldwide market for inflammatory disease treatment is substantial (&amp;gt;$70 billion),
however recent safety scares have been attributed to a number of key drugs. Peptinnovate?s
paradigm shift in potential treatment options will have a profound impact on the lives of
millions of patients, reducing the burden on the healthcare providers and helping to build a
sustainable UK biotech company</gtr:abstractText><gtr:fund><gtr:end>2016-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>100000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710703</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>